INNOCAN PHARMA Corp

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Innocan Pharma Corp's F-1/A filing details an initial public offering of 3,750,000 units, each containing one common share and one warrant, with an anticipated price range of $5.00-$6.00 per unit. Pre-funded units are offered to mitigate ownership concentration limits, with adjusted pricing and warrant structures. The company, an emerging growth company and foreign private issuer, seeks NYSE American listing as a closing condition. The filing incorporates a 65-for-1 reverse share split and updates pricing references to Canadian Securities Exchange data.

2026-04-03 · 0001493152-26-015152

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's FWP filing details an initial public offering of 3,750,000 units, each comprising one common share and one warrant, with an anticipated price range of $5.00-$6.00 per unit. The offering includes up to 3,750,000 pre-funded units to address ownership thresholds, warrants exercisable at $6.875, and a reverse share split effective September 2025. The company, an emerging growth company and foreign private issuer, plans to list on NYSE American pending regulatory approval. Proceeds will be used for operational and strategic purposes.

2026-04-03 · 0001493152-26-015156

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows RW in the pre-IPO sequence.

Innocan Pharma Corp's current F-1 filing represents its initial public offering (IPO) of 3,750,000 units, each consisting of one common share and one warrant. The offering includes up to 3,750,000 pre-funded units for investors exceeding ownership thresholds, with a public offering price range of $5.00-$6.00 per unit. The company plans to list on NYSE American and has implemented a 65-for-1 reverse stock split. As an emerging growth company and foreign private issuer, it faces reduced reporting requirements and unique governance structures.

2026-03-16 · 0001493152-26-010255

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's FWP filing details an initial public offering of 3,750,000 units, each comprising one common share and one warrant, with an anticipated price range of $5.00-$6.00 per unit. The filing also includes an offering of up to 3,750,000 pre-funded units for investors exceeding ownership thresholds, along with warrants. The company plans to list on NYSE American, subject to regulatory approval, and reflects a 65-for-1 reverse share split effective September 2025. The offering includes underwriting discounts, a 45-day option for over-allotments, and disclosures about the company's status as an emerging growth company and foreign private issuer.

2026-03-16 · 0001493152-26-010291

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows EFFECT and ends the active registration process.

Innocan Pharma Corporation has requested the withdrawal of its Registration Statement on Form F-1, effective immediately. The company cited its decision not to proceed with the public offering, emphasizing alignment with the public interest and investor protection. No securities were sold under the registration statement, and the company seeks fee credits for future use.

2026-02-23 · 0001493152-26-007688

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows F-1/A and marks the registration effective.

INNOCAN PHARMA Corp's Form F-1 registration statement became effective on January 30, 2026, following Amendment No. 7. The filing primarily updates Exhibit 5.1 and amends the exhibit index without modifying the prospectus content. The company remains on track for its IPO, with no substantive changes to the offering details disclosed in this effectiveness notice.

2026-01-30 · 9999999995-26-000367

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Innocan Pharma Corp's F-1/A filing (Amendment No. 7) updates the registration statement primarily to reflect an amended Exhibit 5.1 and revised exhibit index. The prospectus remains unchanged, with no preliminary prospectus included. The filing includes detailed disclosures about recent private placements, including unit offerings, stock options, and warrants issued between 2023 and 2025. The company also outlines indemnification provisions for directors and officers, and confirms its status as an emerging growth company under the JOBS Act.

2026-01-07 · 0001493152-26-000726

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Innocan Pharma Corp's F-1/A filing details its initial public offering of 2,350,000 units, each containing one common share and one warrant. The offering price is anticipated between $5.00 and $6.00 per unit, with warrants exercisable at $6.875 per share. The company plans to list shares and warrants on the NYSE American. The filing reflects a 65-for-1 reverse share split effective September 5, 2025, and includes updated market price data as of January 5, 2026. The company is an emerging growth company and foreign private issuer, subject to reduced reporting requirements.

2026-01-06 · 0001493152-26-000539

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's Free Writing Prospectus (FWP) outlines its initial public offering (IPO) of 2,350,000 units, each comprising one common share and one warrant. The offering price is anticipated between $5.00 and $6.00 per unit, with warrants exercisable at $6.875 per share. The company, currently traded on the Canadian Securities Exchange (CSE), plans to list on the NYSE American. The filing includes details of a 65-for-1 reverse share split effective September 5, 2025, and notes the company's status as an emerging growth company and foreign private issuer, subject to reduced reporting requirements.

2026-01-06 · 0001493152-26-000541

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Innocan Pharma Corp's F-1/A filing details its initial public offering of 2,350,000 units, each containing one common share and one warrant. The offering price ranges from $5.00 to $6.00 per unit, with warrants exercisable at $6.875 per share. The company completed a 65-for-1 reverse share split on September 5, 2025, and plans to list shares on the NYSE American. The filing emphasizes its status as an emerging growth company and foreign private issuer, with reduced reporting requirements and non-U.S. governance practices.

2025-12-10 · 0001493152-25-027017

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corp's current FWP filing details an initial public offering of 2,350,000 units, each containing one common share and one warrant. The offering price range is $5.00-$6.00 per unit, with warrants exercisable at $6.875 per share. The filing reflects a 65-for-1 reverse share split effective September 5, 2025, and confirms the company's status as an emerging growth company and foreign private issuer with reduced U.S. reporting requirements.

2025-12-10 · 0001493152-25-027063

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Innocan Pharma Corp's F-1/A filing (Amendment No. 4) updates its registration statement to include Rule 473(b) language for automatic effectiveness 20 days post-filing, updates Exhibit 23.1, and includes recent unregistered securities offerings through July 2025. The filing emphasizes indemnification provisions for directors/officers, ongoing private placements, and warrants, while maintaining its status as an emerging growth company.

2025-10-22 · 0001493152-25-018908

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS/A and supplements the active offering with updated prospectus details.

Innocan Pharma Corporation's FWP filing details an initial public offering of 1,088,157 units, each consisting of one common share and one warrant. The offering price is set at $13.962 per unit, based on the CSE closing price. The filing includes a 65-for-1 reverse share split effective September 5, 2025, and plans to list on Nasdaq. The company emphasizes risks associated with its emerging growth status, foreign private issuer classification, and market volatility.

2025-10-01 · 0001493152-25-016465

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Innocan Pharma Corp's F-1/A filing represents its initial public offering (IPO) of 1,088,157 units, each containing one common share and one warrant. The offering price is set at $13.962 per unit, with warrants exercisable at $17.4525 per share. The company underwent a 65-for-1 reverse share split, affecting all share data. The filing includes details on underwriting, use of proceeds, and risk factors, while confirming the company's status as an emerging growth company and foreign private issuer. The IPO is contingent on listing shares and warrants on Nasdaq.

2025-09-30 · 0001493152-25-016393

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows F-1/A and registers the class of securities for exchange listing.

Innocan Pharma Corp filed an 8-A12B form to register its common shares on Nasdaq, referencing its prior F-1/A registration statement. The filing incorporates by reference the share capital description from the F-1/A and confirms no exhibits are required, as the securities are not registered under Section 12(g). The company remains an emerging growth company and foreign private issuer with reduced reporting requirements.

2025-09-22 · 0001493152-25-014469

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows DRS and supplements the active offering with updated prospectus details.

The current filing is a Free Writing Prospectus (FWP) dated September 12, 2025, relating to a preliminary prospectus dated September 5, 2025. This suggests an update or extension of the previously filed FWP, which was also dated September 5, 2025. The registration number remains unchanged (333-288899).

2025-09-12 · 0001493152-25-013131

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Innocan Pharma Corp's F-1/A filing details its initial public offering of 1,538,462 units, each containing one common share and one warrant. The offering price is set at $9.875 per unit, with warrants exercisable at $12.3438. The filing includes a 65-for-1 reverse share split effective September 5, 2025, and outlines risks related to market volatility, regulatory challenges, and the company's status as an emerging growth and foreign private issuer. The prospectus emphasizes potential dilution and uncertainties in the offering price determination.

2025-09-05 · 0001493152-25-012688

FWP filed

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

First tracked pre-IPO filing for this issuer.

Innocan Pharma Corp's current FWP filing details an initial public offering of 1,538,462 units, each containing one common share and one warrant, with an estimated offering price of $9.875 per unit. The filing incorporates a 65-for-1 reverse share split effective September 5, 2025, and outlines plans to list shares and warrants on Nasdaq. The company, an emerging growth company and foreign private issuer, highlights risks related to its early-stage operations, market volatility, and governance structure.

2025-09-05 · 0001493152-25-012694

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Innocan Pharma Corp's F-1/A filing reflects an updated initial public offering (IPO) structure, incorporating a 65-for-1 reverse share split and revised pricing details. The offering consists of 1,538,462 units, each containing one common share and one warrant, with an estimated public offering price of $9.875 per unit after the reverse split. The filing emphasizes the company's status as an emerging growth company and foreign private issuer, with plans to list on Nasdaq. Key updates include detailed warrant terms, share price adjustments, and risk disclosures related to market volatility and regulatory uncertainties.

2025-08-04 · 0001493152-25-011564

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Innocan Pharma Corp's F-1 filing details its initial public offering of 1,538,461 units, each containing one common share and one warrant, with an estimated price of $9.75. The offering includes a proposed 65-for-1 reverse share split, listing on Nasdaq, and highlights risks related to its emerging growth status, lack of independent directors, and reliance on a single product. The company also notes its foreign private issuer status and reduced reporting requirements.

2025-07-23 · 0001641172-25-020718

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corp's current DRS/A filing (Amendment No. 5) details its initial public offering (IPO) of 961,538 common shares at an estimated price of $10.40 per share, following a 65-for-1 reverse stock split. The filing confirms the company's intention to list on Nasdaq under the symbol INNP, with the offering price subject to adjustment. The document highlights the company's status as an emerging growth company and foreign private issuer, along with risks related to market volatility, regulatory compliance, and reliance on a limited product portfolio.

2025-06-20 · 0001641172-25-015836

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corporation's DRS/A filing details its initial public offering (IPO) of common shares, with an anticipated price range yet to be specified. The company plans to list on Nasdaq under an unspecified symbol, contingent on meeting listing requirements. Currently traded on the Canadian Securities Exchange (CSE), OTCQB, and Frankfurt Stock Exchange (FSE), the offering price may differ from current market prices. As an emerging growth company and foreign private issuer, it faces reduced reporting requirements and potential governance differences. The filing highlights risks, including market volatility, regulatory challenges, and the uncertainty of IPO pricing.

2025-05-15 · 0001641172-25-010821

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corp. is conducting its initial public offering (IPO) of common shares, with an anticipated price range between $ and $ per share. The company intends to list on Nasdaq under an unspecified symbol. Currently, its shares are traded on the Canadian Securities Exchange (CSE), OTCQB, and Frankfurt Stock Exchange (FSE). The offering price may be discounted relative to current market prices, and the company is an emerging growth company and foreign private issuer subject to reduced reporting requirements.

2025-05-12 · 0001641172-25-009654

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Innocan Pharma Corporation's current DRS/A filing outlines its initial public offering (IPO) of common shares, with an anticipated price range of $ to $ per share. The company, a pharmaceutical tech firm operating in Pharmaceuticals and Consumer Wellness segments, plans to list on Nasdaq. It highlights pre-clinical studies for cannabinoid-based therapies, current trading on CSE, OTCQB, and FSE, and risks related to unverified human trials and market volatility. The filing also notes its status as an emerging growth company and foreign private issuer.

2025-05-01 · 0001641172-25-008062

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Innocan Pharma Corp's DRS/A filing outlines its initial public offering (IPO) of common shares, with an anticipated price range and plans to list on a national securities exchange. The company operates in two segments: Pharmaceuticals (developing cannabinoid-based drug delivery technologies) and Consumer Wellness (online sales). The filing highlights risks related to market volatility, regulatory uncertainties, and reliance on its LPT-CBD platform. The company is an emerging growth company with reduced reporting requirements.

2025-03-28 · 0001641172-25-001089

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Innocan Pharma Corp. is conducting its initial public offering (IPO) of common shares, aiming to list on a national securities exchange. The company operates in two segments: Pharmaceuticals, focused on developing cannabinoid-based drug delivery technologies, and Consumer Wellness, involving online sales. As an emerging growth company and foreign private issuer, it faces risks related to market volatility, regulatory compliance, and unproven technologies. The offering price may be discounted relative to current market prices, and listing depends on regulatory approval.

2024-12-31 · 0001493152-24-052663

INNOCAN PHARMA Corp

Filing Timeline

2 comparable deals

Recent News